Compare CleanSpark Inc (CLSK) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CleanSpark Inc vs BIO-TECHNE Corp — how do they compare? CleanSpark Inc trades at $11.7 (market cap $2.98B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp is far larger — about 3.8× CleanSpark Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while CleanSpark Inc pays none. Which is the better fit depends on your goals.
| CLSK | TECH | |
|---|---|---|
Market Cap | $2.98B | $11.24B |
Sector | Technology | Health |
52-Week High | $23.20 | $72.29 |
52-Week Low | $8.18 | $43.31 |
Enterprise Value | $3.97B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CleanSpark (CLSK) trades at $12.30, down 3.53% amid a bearish technical outlook despite unanimous analyst buy ratings. The stock faces fundamental challenges with four consecutive quarterly earnings misses and negative profitability margins (-146.9% net income margin). Recent developments include a strategic pivot toward AI data centers, highlighted by a 20-year, $6.6 billion lease agreement in Sandersville, Georgia, which aims to diversify revenue streams beyond Bitcoin mining.
The stock presents a high-risk, high-reward opportunity with analysts projecting 94% upside to a $23.89 consensus target. Key risks include persistent earnings underperformance, negative cash flow from operations, and execution challenges in the AI infrastructure transition. Investors must weigh the long-term potential of the data center pivot against near-term financial volatility and dilution concerns.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CleanSpark Inc
CleanSpark is a leading Bitcoin mining company that operates high-density data centers. It focuses on using sustainable energy to power its mining fleet and provides digital infrastructure for the blockchain ecosystem.
Read more on CLSK →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
